Hormonal Birth Control as a Clotting Risk Factor: A Vascular Surgeon's Perspective

Scope note: This article covers hormonal contraception strictly as a clotting risk factor — the same lens used for any risk factor seen in clinic. It does not cover contraceptive effectiveness or choice; those questions belong with your OB/GYN.

In vascular clinic, hormonal birth control comes up constantly as one line in a longer list — alongside smoking, recent surgery, obesity, and family history — when assessing clotting risk.

The Mechanism, From the Vein's Point of View

Combined pills use synthetic estrogen paired with a progestin. That estrogen prompts the liver to produce more clotting factors while reducing natural anti-clotting mechanisms. The number used in clinic: combined pills raise VTE risk roughly 3 to 7 times versus non-use, depending on estrogen dose and progestin type. Baseline VTE incidence in healthy women is roughly 2–4 per 10,000 per year without hormonal contraception, rising to 8–10 per 10,000 with combined pill use — for context, pregnancy carries considerably higher risk than either figure.

The Detail Most Articles Skip

Combined pills carry the risk above. Progestin-only pills, the hormonal IUD, and the implant carry little to no added clotting risk. Among combined pills, newer-generation progestins (drospirenone, desogestrel) show modestly higher risk than levonorgestrel-containing formulations.

Warning Signs

Same signs as any elevated clotting risk: one-sided swelling, warmth, redness, or a dull ache. Sudden shortness of breath or chest pain signals a possible pulmonary embolism — a medical emergency.

What's Worth Raising With Your Doctors

Mention smoking, migraines with aura, age over 35, elevated BMI, or family history of clots to whoever manages your contraception. If facing surgery or long travel while on combined hormonal contraception, flag it — the risks combine.

What the Evidence Shows

Meta-analyses consistently place the risk increase at 3–7x, with additive risk from immobilization, age, BMI, and thrombophilia. Routine genetic thrombophilia screening before prescribing is not currently recommended for the general population by major guideline bodies — that prescribing decision sits with your OB/GYN.

Vascular Surgeon's Take

The specific detail I look for that most patients don't think to volunteer is which generation of progestin they're on, not just "which pill." A patient switching from a levonorgestrel-based pill to a drospirenone-based one after a bad reaction, for instance, may be inadvertently increasing her clotting risk profile — a detail that lives in the prescription itself, not in anything she'd notice day to day.

References
Dragoman MV, et al. — A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. International Journal of Gynecology & Obstetrics, 2018. DOI: 10.1002/ijgo.12455
van Vlijmen EFW, et al. — Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 2016. DOI: 10.1111/jth.13349
American Society for Reproductive Medicine (ASRM) — Combined hormonal contraception and the risk of venous thromboembolism: a guideline. Fertility and Sterility, 2016. DOI: 10.1016/j.fertnstert.2016.09.027

Recommended Reading
Does the Pill Really Raise Your Risk of Blood Clots?
Calf Cramp or Blood Clot? How to Tell the Difference in 60 Seconds